FLI-06

FLI-06 is a small molecule, dihydropyridine-based inhibitor that disrupts the early secretory pathway at a step before cargo exit from the endoplasmic reticulum (ER), leading to broad inhibition of protein secretion. Its best characterized effect is the inhibition of the Notch signaling pathway, which it blocks by preventing maturation, glycosylation, and surface expression of Notch receptors. FLI-06 reduces Notch receptor and downstream gene expression at both mRNA and protein levels, blocks cell proliferation, induces cell cycle arrest (G1 phase), and promotes apoptosis in various cancer cell models, including tongue squamous cell carcinoma, esophageal squamous cell carcinoma, and head and neck squamous cell carcinoma. It has also been shown to reduce the expression of LSD1 (KDM1A), a histone demethylase, in some contexts. FLI-06 is investigational and used in preclinical research, primarily as a tool compound to study Notch pathway biology and secretory pathway dynamics[1][2][3][5][7][8][9][10][11].

Other names

cyclohexyl 2,7,7-trimethyl-4-(4-nitrophenyl)-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate